Skip to main content

Table 2 Weighted mean FEV1 0–24 h at Week 12

From: Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

 Study 207608 (mPP population)Study 207609 (mPP population)Pooled analysis (ITT population)
FF/UMEC/VI
N = 358
BUD/FOR+TIO
N = 362
FF/UMEC/VI
N = 354
BUD/FOR+TIO
N = 357
FF/UMEC/VI
N = 729
BUD/FOR+TIO
N = 731
n282272274277674665
LS mean (95% CI), mL1210 (1191, 1230)1195 (1175, 1215)1185 (1163, 1206)1174 (1153, 1195)1199 (1185, 1213)1185 (1171, 1198)
LS mean (SE) change from baseline, mL45 (26, 65)30 (10, 50)39 (18, 61)29 (7, 50)42 (29, 56)28 (14, 42)
Treatment difference (95% CI), mL15 (−13, 43)11 (−20, 41)14 (−5, 34)
  1. n number of patients with analyzable data at the current time point
  2. BUD budesonide; CI confidence interval; FEV1 forced expiratory volume in 1 s; FF fluticasone furoate; FOR formoterol; ITT intent-to-treat; LS least squares; mPP modified per protocol; SE standard error; TIO tiotropium; UMEC umeclidinium; VI vilanterol